上一节课程，刘红兵老师为我们介绍了MPE的诊断和传统治疗方法，本次课程将继续同一讲题，介绍MPE的细胞因子药物治疗进展。

近年来生物免疫制剂发展较为迅速，临床中应用较为广泛。它既能参与免疫调节，也能起到抗肿瘤的作用。此类药物一般患者可以耐受，毒副作用较小，减少了骨髓抑制及消化道反应的发生。肿瘤坏死因子、血管内皮生长因子等药物都展现出不错的临床结果，多个研究已证实其在MPE中的应用价值。然而，未来仍有许多有待继续研究的课题在等待着我们。

本节课程，刘红兵老师深入讲解这些潜力药物的机制和临床进展，并且在课程的最后还有ATS/STS/STF临床实践指南的重点解读，一起来学习吧。

内容提要：

1. 肿瘤坏死因子（TNF）治疗MPE

2. VEGF抗体治疗MPE

3. ATS/STS/STR 恶性胸腔积液临床实践指南重点解读

(最下方有课程中涉及的文献信息）

更多精彩内容，可下载壹生APP观看，或添加小助手微信号（13269296986，注明“恶性胸腹水”）咨询。

文献信息：

1. 恶性胸腔积液诊断与治疗专家共识，中华内科杂志，2014，53(3):252-256

2. 张玉, 等. 恶性胸腔积液综合治疗进展[J]. 现代生物医学进展, 2012,12(17):3358-3361.

3.注射用重组改构人肿瘤坏死因子治疗国人恶性胸、腹腔积液的前瞻性多中心临床研究[J]. 临床肿瘤学杂志, 2016, 21(7).

4. 晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识，中华结核和呼吸杂志.2016,39(11):839-849.

5. 秦叔逵,等.腔内应用重组人血管内皮抑制素和/或顺铂治疗恶性胸腹腔积液的前瞻性、随机对照、全国多中心Ⅲ期临床研究[J].临床肿瘤学杂志,2017,22(3):193-202.

6. Frances Balkwill. Tumour necrosis factor and cancer. Nature reviews cancer, 9, 2009:361-371

7. Balkwill, F., Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9 (5), 361-71.

8. Du, N, et al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion. Oncol Rep 2013, 29 (6), 2332-40.

9. Feller-Kopman, D. J, et al. A. A., Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med 2018, 198 (7), 839-849.

10. Ishii, H, et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer 2004, 45 (3), 325-37.

5. Kitamura, K, et al. Yoshimura, A.; Gemma, A., Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol 2013, 71 (2), 457-61.

6. Lejeune, F. J, Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 2002, 110 (4), 433-5.

7. Limaverde-Sousa, G, et al. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev 2014, 40 (4), 548-57.

8. Ma, X, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One 2012, 7 (12), e53449.

9. Spella, M, et al.  Switching off malignant pleural effusion formation-fantasy or future? J Thorac Dis 2015, 7 (6), 1009-20.

10. Tamiya, M, et al. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion. Med Oncol 2013, 30 (3), 676.

11. Yano, S, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000, 157 (6), 1893-903.